// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Toshinori Ozaki1, Mizuyo Nakamura1, Takehiro Ogata1, Meijie Sang1, 2, Hiroyuki Yoda3, Kiriko Hiraoka3, Meixiang Sang1, 4, Osamu Shimozato1 1Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Chiba, Japan 2Department of Regenerative Medicine, Graduate School of Medicine and Pharmatheutical Science, University of Toyama, Toyama, Japan 3Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan 4Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China Correspondence to: Toshinori Ozaki, email: tozaki@chiba-cc.jp Keywords: gemcitabine, mutant p53, pancreatic cancer, RUNX2, TAp63 Received: February 16, 2016 Accepted: September 25, 2016 Published: October 04, 2016